Microba Life Sciences Limited (MAP) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. I'm very pleased to share an update on our progress following the close of the quarter ended 31 March, 2024. This is our standard disclaimer. I'll just move quickly past that. Firstly, I want to take a moment to recap on Microbe. Microbe is a medical diagnostic and clinical stage therapeutics company that's unlocking the medical application of the microbiome, which is the trillions of organisms that live in and on our body which are critical to our health and the development of disease. Founded on world-leading metagenomic microbiome and microbial genomics analysis technology with a clear vision that that technology would lead to new diagnostic testing solutions that become a routine part of healthcare and lead us to the discovery and development of novel drugs for major chronic diseases. We've invested over multiple years to develop two diagnostic testing products, MetaExplore for diagnosing gastrointestinal disorders launched just last year and MetaPanel for diagnosing gastrointestinal pathogens launched just last month together with Sonic Healthcare. In parallel, we've invested in three therapeutic programs spanning inflammatory bowel disease, immuno-oncology and autoimmune disease. We've successfully completed a first in human phase one clinical trial are at an advanced stage of preparing for a phase two trial and progressing a compelling pipeline of preclinical leads for multiple indications. And this has not happened overnight. It's been years of work that's now materializing in a significant commercial opportunity that lays in front of us. Up front, I want to highlight some of the recent milestones and key achievements from the quarter. Firstly, let me take you through the strong numbers We delivered 4 million in revenue, which represen...